
UnicoCell — Investor Relations & Filings
UnicoCell Biomed Co., Ltd. specializes in regenerative medicine, focusing on the research, development, and clinical application of stem cell technologies. The company’s operations are centered on three primary axes: the development of novel stem cell therapeutics, the production of stem cell-derived exosomes, and the provision of cell manufacturing and Contract Development and Manufacturing Organization (CDMO) services. Its lead candidate, ELIXCYTE, is an adipose-derived stem cell therapy undergoing Phase 3 clinical trials for indications such as knee osteoarthritis and chronic kidney disease. Additionally, the company maintains an allogeneic stem cell bank and provides autologous adipose-derived stem cell therapy services. Utilizing patented manufacturing processes and proprietary technology, UnicoCell offers integrated solutions from research to large-scale production to address unmet medical needs in the regenerative therapy sector.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 本公司脂肪幹細胞新藥ELIXCYTE治療膝骨關節炎 (Knee Osteoarthritis)之人體臨床試驗,向衛生福利部 提出申請臨床試驗設計變更。 | 2026-05-29 | Chinese | |
| 功能性委員會成員 | 2026-05-21 | Chinese | |
| 功能性委員會成員 | 2026-05-21 | Chinese | |
| 公告本公司董事會委任薪資報酬委員會委員 | 2026-05-20 | Chinese | |
| 公告本公司審計委員會委員異動 | 2026-05-20 | Chinese | |
| 公告本公司董事會選任董事長 | 2026-05-20 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47889775 | 本公司脂肪幹細胞新藥ELIXCYTE治療膝骨關節炎 (Knee Osteoarthritis)之人體臨床試驗,向衛生福利部 提出申請臨床試驗設計變更。 | 2026-05-29 | Chinese | ||
| 46707409 | 功能性委員會成員 | 2026-05-21 | Chinese | ||
| 46707411 | 功能性委員會成員 | 2026-05-21 | Chinese | ||
| 46586514 | 公告本公司董事會委任薪資報酬委員會委員 | 2026-05-20 | Chinese | ||
| 46586515 | 公告本公司審計委員會委員異動 | 2026-05-20 | Chinese | ||
| 46586516 | 公告本公司董事會選任董事長 | 2026-05-20 | Chinese | ||
| 46586518 | 公告本公司115年股東常會通過解除董事競業禁止之限制 | 2026-05-20 | Chinese | ||
| 46584900 | 公告本公司115年股東常會重要決議事項 | 2026-05-20 | Chinese | ||
| 46584942 | 公告本公司115年股東常會董事改選當選名單(含獨立董事) | 2026-05-20 | Chinese | ||
| 46577281 | 公司治理組織架構 | 2026-05-20 | Chinese | ||
| 45809303 | 115年第1季財務報告書 — 202601_6794_AI2.pdf | 2026-05-12 | Chinese | ||
| 45746236 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45741522 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741333 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45740917 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMAGION BIOSYSTEMS LIMITED
Develops nanoparticle-based imaging for non-invasive cancer…
|
IBX | AU | Professional, scientific and te… |
|
IMCB PJSC
Biotechnology company specializing in personal stem cell ba…
|
GEMA | RU | Professional, scientific and te… |
|
Immuneering Corp
Clinical-stage oncology company developing medicines using …
|
IMRX | US | Professional, scientific and te… |
|
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Clinical-stage biotech developing dual-approach immuno-onco…
|
1541 | HK | Professional, scientific and te… |
|
IMMUNIC, INC.
Develops oral small molecule therapies for chronic inflamma…
|
IMUX | US | Professional, scientific and te… |
|
Immunovant, Inc.
Clinical-stage immunology company developing anti-FcRn anti…
|
IMVT | US | Professional, scientific and te… |
|
IMMUPHARMA PLC
Specialty biopharmaceutical company developing peptide-base…
|
IMM | GB | Professional, scientific and te… |
|
IMMUTEP LIMITED
Develops LAG-3 targeting immunotherapies for cancer and aut…
|
IMM | AU | Professional, scientific and te… |
|
IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for …
|
IMMP | US | Professional, scientific and te… |
|
IMPACT BIOMEDICAL INC.
Develops biopharmaceutical products and technologies to pro…
|
IBO | US | Professional, scientific and te… |
UnicoCell via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52633/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52633 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52633 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52633 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52633}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for UnicoCell (id: 52633)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.